Skip to main content
SpringerLink
Log in

Selected Immuno-Histochemical Markers in Curettage Specimens and their Correlation with Final Pathologic Findings in Endometrial Cancer Patients

  • Research
  • Published:
Pathology & Oncology Research

Abstract

To assess the immuno-histochemical expression of various markers in, endometrial biopsies of patients with endometrial cancer, and to correlate their expression with the final pathologic findings. Sixty-two patients with primary endometrial cancer who underwent surgical treatment were included in this study. Immuno-histochemical expression of estrogen receptor (ER), progesterone receptor (PR), p53, bcl-2, Her-2/neu and Ki-67 were assessed in curettage specimens, and review of the final pathology report from hysterectomy specimens was carried out. The expression of these markers in curettage was correlated with the final tumor characteristics obtained on hysterectomy specimens. Both ER and PR were significantly more expressed in endometrioid type (EC) than non- endometrioid type (NEC) (P value of 0.004 and 0.012). On the contrary, P53, Her-2 and Ki-67 showed higher positivity in NEC than EC (P value of 0.005, 0.025 and 0.002). Positive expression of ER and PR was significantly associated with low grade tumors and superficial myometrial invasion, whereas positive expression of Her-2 and Ki-67 was significantly associated with higher grade lesions, and deep myometrial invasion. Moreover, a statistically significant inverse relationship was observed between the positivity of P53, Her-2 and Ki-67 and the positivity of ER, PR. We found that determination of immuno-histochemical markers in curettage specimens might be helpful in predicting the final pathologic findings in patients with endometrial cancer. This might be helpful in planning the extensivity of the surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59(4):225–249

    Article  PubMed  Google Scholar 

  2. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17

    Article  PubMed  CAS  Google Scholar 

  3. Announcements (1989) FIGO stages-1988 revision. Gynecol Oncol 35:125–127

    Article  Google Scholar 

  4. Yokoyama Y, Maruyama H, Sato S et al (1997) Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers. Gynecol Oncol 64:411–417

    Article  PubMed  CAS  Google Scholar 

  5. Mariani A, Keeney GL, Aletti G et al (2004) Endometrial carcinoma: paraaortic dissemination. Gynecol Oncol 92:833–838

    Article  PubMed  Google Scholar 

  6. Kinkel K, Kaji Y, Yu KK et al (1999) Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 212:711–718

    PubMed  CAS  Google Scholar 

  7. Larson DM, Connor GP, Broste SK, Krawisz BR, Johnson KK (1996) Prognostic significance of gross myometrial invasion with endometrial cancer. Obstet Gynecol 88:396–398

    Article  Google Scholar 

  8. Zorlu CG, Kuscu E, Ergun Y, Aydogdu T, Cobanoglu O, Erdas O (1993) Intraoperative evaluation of prognostic factors in stage I endometrial cancer by frozen section: how reliable? Acta Obstet Gynecol Scand 72:382–385

    Article  PubMed  CAS  Google Scholar 

  9. Sanjuán A, Cobo T, Pahisa J, Escaramís G, Ordi J, Ayuso JR, Garcia S, Hernández S, Torné A, Martínez Román S, Lejárcegui JA, Vanrell JA (2006) Preoperative and intraoperative assessment of myometrial invasion and histologic grade in endometrial cancer: role of magnetic resonance imaging and frozen section. Int J Gynecol Cancer 16(1):385–390

    Article  PubMed  Google Scholar 

  10. Vorgias G, Hintipas E, Katsoulis M, Kalinoglou N, Dertimas B, Akrivos T (2002) Intraoperative gross examination of myometrial invasion and cervical infiltration in patients with endometrial cancer: decision-making accuracy. Gynecol Oncol 85:483–486

    Article  PubMed  Google Scholar 

  11. Geisinger KR, Marschall RB, Kute TE, Homesley HD (1986) Correlation of female sex steroid hormone receptors with histologic and ultrastructural differentiation in adenocarcinoma of endometrium. Cancer 58:1506–1517

    Article  PubMed  CAS  Google Scholar 

  12. Kleine W, Maier T, Geyer H, Phleiderer A (1990) Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 38:59–65

    Article  PubMed  CAS  Google Scholar 

  13. Creasman WT, Soper JT, McCarty KS Jr, McCarty KS Sr, Hinshaw W, Clarke-Pearson DL (1985) Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 151:922–932

    PubMed  CAS  Google Scholar 

  14. Ferrandina G, Ranelletti FO, Gallotta V et al (2005) Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER) and progesterone (PR), p53, Ki-67, and neu protein in endometrial cancer. Gynecol Oncol 98:383–389

    Article  PubMed  CAS  Google Scholar 

  15. Halperin R, Zehavi S, Habler L et al (2001) Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 22:122–126

    PubMed  CAS  Google Scholar 

  16. Kadar N, Malfetano JH, Homesley HD (1993) Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol 50:281–286

    Article  PubMed  CAS  Google Scholar 

  17. Morris PC, Anderson JR, Anderson B et al (1995) Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol 56:406–411

    Article  PubMed  CAS  Google Scholar 

  18. Geisler JP, Wiemann MC, Zhou Z et al (1996) p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol 61:245–248

    Article  PubMed  CAS  Google Scholar 

  19. Cherchi PL, Marras V, Capobianco G et al (2001) Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma. Eur J Gynaecol Oncol 22:451–453

    PubMed  CAS  Google Scholar 

  20. Lax SF, Pizer ES, Ronnett BM et al (1998) Clear cell carcinoma of the endometrium is characterized by adistinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 29:551–558

    Article  PubMed  CAS  Google Scholar 

  21. Ohkouchi T, Sakuragi N, Watari H et al (2002) Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma. Am J Obstet Gynecol 187:353–359

    Article  PubMed  CAS  Google Scholar 

  22. Lukes AS, Kohler MF, Pieper CF et al (1994) Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 73:2380–2385

    Article  PubMed  CAS  Google Scholar 

  23. Mariani A, Sebo TJ, Webb MJ et al (2003) Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prev 27:434–441

    Article  PubMed  Google Scholar 

  24. Salvesen HB, Iversen OE, Akslen LA (1998) Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res 4:2779–2785

    PubMed  CAS  Google Scholar 

  25. Salvesen HB, Iversen OE, Akslen LA (1999) Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 17:1382–1390

    PubMed  CAS  Google Scholar 

  26. Erdem O, Erdem M, Dursum A et al (2003) Angiogenesis, p53 and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathological variables. Int J Gynecol Pathol 22:254–260

    Article  PubMed  Google Scholar 

  27. Sakuragi N, Ohkouchi T, Hareyama H et al (1998) Bcl-2 expression and prognosis of patients with endometrial carcinoma. Int J Cancer 79:153–158

    Article  PubMed  CAS  Google Scholar 

  28. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW (2000) Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 13(4):379–388

    Article  PubMed  CAS  Google Scholar 

  29. Appel MLM, Edelweis MI, Fleck J et al (2008) p53 and bcl-2 as prognostic markers in endometrial carcinoma. Pathol Oncol Res 14:23–30

    Article  PubMed  CAS  Google Scholar 

  30. Markova I, Duskova M, Lubusky M, Kudela M, Zapletalová J, Procházka M, Pilka R (2010) Selected immunohistochemical prognostic factors in endometrial cancer. Int J Gynecol Cancer 20(4):576–582

    Article  PubMed  Google Scholar 

  31. Konecny GE, Agarwal R, Keeney GA, Winterhoff B, Jones MB, Mariani A, Riehle D, Neuper C, Dowdy SC, Wang HJ, Morin PJ, Podratz KC (2008) Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol Oncol 109(2):263–269

    Article  PubMed  CAS  Google Scholar 

  32. Sobel G, Németh J, Kiss A, Lotz G, Szabó I, Udvarhelyi N, Schaff Z, Páska C (2006) Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma. Gynecol Oncol 103(2):591–598

    Article  PubMed  CAS  Google Scholar 

  33. Dupont J, Wang X, Marshall DS, Leitao M, Hedvat CV, Hummer A et al (2004) Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol 94(2):449–455

    Article  PubMed  CAS  Google Scholar 

  34. Ohno S, Dohi S, Ohno Y, Kyo S, Sugiyama H, Suzuki N, Inoue M (2009) Immunohistochemical detection of WT1 protein in endometrial cancer. Anticancer Res 29(5):1691–1695

    PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Dr Yousef Khader, Department Of public health, for his help in the analysis of the results.

Disclosure of Interests

The authors declare that they have no conflicts of interest.

Funding

The study was funded by the research Deanship at Jordan University of Science and Technology

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Jordan University of Science and Technology, P.O. Box 2954, Irbid, 21110, Jordan

    Basil R. Obeidat

  2. Department of Pathology and Laboratory Medicine, Jordan University of Science and Technology, Irbid, Jordan

    Ismail I. Matalka & Alia A. Mohtaseb

  3. Department of Pathology, King Hussein Medical Centre, Amman, Jordan

    Nabih S Al-Kaisi

Authors
  1. Basil R. Obeidat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ismail I. Matalka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alia A. Mohtaseb
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nabih S Al-Kaisi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Basil R. Obeidat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Obeidat, B.R., Matalka, I.I., Mohtaseb, A.A. et al. Selected Immuno-Histochemical Markers in Curettage Specimens and their Correlation with Final Pathologic Findings in Endometrial Cancer Patients. Pathol. Oncol. Res. 19, 229–235 (2013). https://doi.org/10.1007/s12253-012-9573-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-012-9573-1

Keywords

Search

Navigation